Business
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
VANCOUVER, BC / ACCESS Newswire / December 11, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent application intended to cover a needle-free delivery platform ...
About this update from Lir Life Sciences Corp.
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / December 11, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent application intended to cover a needle-free delivery platform for GLP/GIP[1]-based therapies used in obesity and metabolic disease. LIR filed the provisional patent application titled "Transdermal and Lingual Delivery System for GLP-1 Inhibitors" with the United States Patent and Trademark Office (USPTO). The filing is intended to protect LIR's approach to delivering these therapies through the skin, with the goal of replacing or reducing the need for injections.","length":693,"tagName":"p"},{"type":"text","content":"The provisional application describes how established GLP/GIP drugs for obesity and type 2 diabetes can be paired with proprietary carrier technology to cross the outer layer of the skin and reach the bloodstream at therapeutic levels. This includes transdermal formats such as patches, creams or gels. The filing encompasses both the specific compositions and the methods of administration for GLP/GIP-based therapies and related peptide drugs.","length":445,"tagName":"p"},{"type":"text","content":"From a development perspective, this provisional patent application is intended to support LIR's broader strategy to build a platform, rather than a single product. By focusing on the GLP/GIP class as a whole, the technology is intended to be compatible with multiple existing and future GLP- and GIP-based medicines, and to support potential combination products.","length":368,"tagName":"p"},{"type":"text","content":"The provisional application also complements the Company's ongoing preclinical program, including the controlled comparative mouse study recently announced by LIR (see Company press release December 10, 2025). That study is designed to test whether a CPP-enabled, skin-applied formulation of a GLP/GIP-based therapy can achieve meaningful biological activity in a small animal model using a standard glucose tolerance test. Data from such studies are expected to inform final formulation choices and to support the transition from provisional protection into longer-term patent coverage and potential IND-enabling work.","length":623,"tagName":"p"},{"type":"text","content":"For patients and ...